

# Contents

|  |           |
|--|-----------|
| Contributors   | ix        |
| Acknowledgements   | xii       |
| Foreword   | xiii      |
| <b>1 Definition: Translational and Personalised Medicine,<br/>Biomarkers, Pharmacodynamics</b>   | <b>1</b>  |
| Introduction   | 1         |
| Defining Translational Research and Personalised Medicine  | 2         |
| Prognostic Biomarkers  | 3         |
| Predictive Biomarkers  | 5         |
| Biomarker Selection and Validation   | 6         |
| Pharmacodynamics and Drug Development  | 7         |
| Surrogate Endpoints  | 8         |
| Conclusions and Future Directions  | 9         |
| Further Reading  | 10        |
| <b>2 Biology of Normal and Tumour Cells (Self-sufficiency and<br/>Insensitivity to Anti-proliferative Signals, Apoptosis,<br/>Limitless Replicative Potential)</b> | <b>12</b> |
| Normal Cell Structure  | 12        |
| Normal Cell Properties   | 14        |
| Cancer Cell Biology  | 19        |
| Conclusion   | 26        |
| Further Reading  | 27        |

|          |   |    |
|----------|---|----|
| <b>3</b> | <b>Principles of Tumour Immunology and Immunotherapy</b>                          | 28 |
|          | Introduction  | 28 |
|          | Innate and Adaptive Immunity  | 28 |
|          | Immunosurveillance of Cancer  | 35 |
|          | Tumour Antigens   | 35 |
|          | Immune Escape Mechanisms  | 37 |
|          | Immunotherapy   | 38 |
|          | Concluding Remarks  | 42 |
|          | Further Reading   | 43 |
| <b>4</b> | <b>Classes of Drugs and Mechanisms of Action</b>                                  | 44 |
|          | Introduction  | 44 |
|          | Chemotherapeutics   | 44 |
|          | Molecularly-targeted Anti-cancer Drugs  | 47 |
|          | Conclusions   | 53 |
|          | Further Reading   | 54 |
| <b>5</b> | <b>Techniques and New Diagnostic Technologies<br/>(Limitations, Applications)</b> | 55 |
|          | Introduction  | 55 |
|          | High-throughput Technologies for Molecular Genotyping<br>and Their Applications   | 57 |
|          | Biomarker Identification Through Liquid Biopsy                                    | 61 |
|          | Conclusions and Future Perspectives   | 65 |
|          | Further Reading   | 66 |
| <b>6</b> | <b>Angiogenesis, Tissues Invasion, and Metastasis</b>                             | 67 |
|          | Introduction  | 67 |
|          | Physiological and Pathological Angiogenesis                                       | 68 |
|          | Tumour-associated Vasculature   | 69 |
|          | Anti-angiogenic Therapy in Cancer   | 71 |
|          | Resistance to Anti-angiogenic Therapy   | 73 |
|          | Biomarkers of Tumour Angiogenesis   | 74 |
|          | Invasion and Metastasis   | 74 |
|          | The Metastatic Cascade  | 74 |
|          | Metastatic Organotropism  | 77 |

|          |   |            |
|----------|---|------------|
|          | Metastatic Dormancy   | 78         |
|          | Concluding Remarks and Outlook  | 79         |
|          | Further Reading   | 80         |
| <b>7</b> | <b>Mutations, Genomic Instability, and Cancer Evolution</b>   | <b>81</b>  |
|          | Introduction and Definitions  | 81         |
|          | Description of the Processes Involved in Mutation and Heterogeneity Generation and Tumour Evolution | 82         |
|          | Technical Procedures to Assess Mutations, Genomic Instability, Heterogeneity, and Ongoing Evolution | 86         |
|          | Clinical Trial Results  | 88         |
|          | Predictive and/or Prognostic Biomarkers of Potential Clinical Relevance                             | 89         |
|          | Potential Future Developments   | 90         |
|          | Further Reading   | 91         |
| <b>8</b> | <b>Avoiding Immune Destruction-Immunotherapy</b>  | <b>92</b>  |
|          | Immune Escape as a Hallmark of Cancer   | 92         |
|          | Description of the Processes Involved in their Essential/Critical Steps                             | 92         |
|          | Technical Procedures Involved   | 97         |
|          | Predictive and/or Prognostic Biomarkers of Clinical Relevance                                       | 98         |
|          | Clinical Results  | 99         |
|          | Potential Future Developments   | 101        |
|          | Further Reading   | 102        |
| <b>9</b> | <b>Tumour-promoting Inflammation</b>  | <b>103</b> |
|          | Introduction  | 103        |
|          | The Immune System Within the Cancer Context   | 106        |
|          | How Does Chronic Inflammation Promote Established Cancers?  | 108        |
|          | How Does Chronic Inflammation Predispose To Carcinogenesis?   | 109        |
|          | Therapeutic Strategies to Target Cancer-promoting Inflammation                                      | 110        |
|          | Further Reading   | 112        |

|           |  |     |
|-----------|--|-----|
| <b>10</b> | <b>Molecular Diagnostics and Biomarkers:</b>   |     |
|           | <b>Application and Limits</b>  | 113 |
|           | Introduction   | 113 |
|           | Biomarkers: Definition and Subtypes  | 118 |
|           | Molecular Biomarkers: Method Validation and<br>Clinical Qualification                                      | 119 |
|           | Technical Procedures and Associated Challenges Involved<br>in Molecular Biomarker Development and Analysis | 120 |
|           | Predictive and/or Prognostic Molecular Biomarkers of<br>Clinical Relevance                                 | 122 |
|           | Clinical Results   | 122 |
|           | Potential Future Developments  | 123 |
|           | Further Reading  | 124 |
|           | <b>Index</b>   | 125 |